Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies.
We investigated the in vitro cytotoxic potential of Auger electron-emitting radionuclides delivered to the cytoplasm or, more specifically, to lysosomes, via antibodies. The antibody (Ab) used was LL1, which is specific for CD74, an epitope of the major histocompatibility complex (MHC) class II antigen invariant chain, Ii, present on the cell surface. It is taken up in large amounts, approximately 10(7) Ab molecules per cell per day, and delivered to lysosomes. The radioisotopes tested included (111)In, 99mTc and 125I. With sufficient specific activity, approximately 10 mCi/mg Ab, all of these isotopes were potent cytotoxic agents. 125I was active only if a "residualizing" form was used, meaning a form that is trapped within cells after catabolism of the Ab to which it was conjugated (conventional oxidative iodination produces a non-residualizing label). The conjugates of (111)In and 99mTc used are known to be residualizing. One hundred percent cell kill in vitro was obtained with (111)In and 125I, under conditions in which a non-reactive control Ab, conjugated in the same way, produced no significant toxicity. 99mTc was also potent and specific, but appeared somewhat less active than the other isotopes under the conditions evaluated. Although few Abs are accreted by cells at the same rate as LL1, it may be possible to use other Abs to deliver similar amounts of radioactivity, if Abs with higher specific activity can be produced. Such conjugated radioisotopes may be useful for attacking tumor cells in vivo, particularly for single cells or micrometastases.
Griffiths
G L
GL
Immunomedics, Inc., Morris Plains, NJ, USA.
Govindan
S V
SV
Sgouros
G
G
Ong
G L
GL
Goldenberg
D M
DM
Mattes
M J
MJ
D000906:Antibodies; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology; D002470:Cell Survival / Q000528:radiation effects*; D004307:Dose-Response Relationship, Radiation; D004583:Electrons; D005720:Gamma Rays; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D007205:Indium Radioisotopes / Q000493:pharmacokinetics* / Q000633:toxicity; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics* / Q000633:toxicity; D007700:Kinetics; D016393:Lymphoma, B-Cell; D008285:Major Histocompatibility Complex / Q000276:immunology; D016499:Radioimmunotherapy / Q000379:methods; D013667:Technetium / Q000493:pharmacokinetics* / Q000633:toxicity; D014407:Tumor Cells, Cultured
D000906:Antibodies; D000944:Antigens, Differentiation, B-Lymphocyte; D000951:Antigens, Neoplasm; D000949:Histocompatibility Antigens Class II; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; C045084:invariant chain; D013667:Technetium